COVID-19 Webinar: The Implications of Long COVID
Long COVID ― a general term for the continuation or appearance of symptoms weeks or months after someone is infected with COVID-19 ― is a serious public health concern with major implications for the delivery of health care services long after the pandemic is over. According to an article in the BMJ (the British Medical Journal), approximately 10% of people experience prolonged illness after COVID-19. Some researchers believe the number of long-haul COVID patients could be as high as 30%. Given those numbers, combined with the lack of current knowledge about the duration of long COVID symptoms or why they occur, pressure will only increase on hospitals and health systems already stretched to the limit by the pandemic. At least 6 specialized clinics have popped up across Canada in the past year to treat the needs of long-haul patients. An expert panel will discuss what we know so far about long COVID, provide an update on long COVID clinics, and share their views on what needs to be done to ensure quality of care as the number of “long haulers” grows. Panel:
Dr. Angela Cheung, University of Toronto and Co-lead of CANCOV (Canadian COVID-19 Prospective Cohort Study)
Dr. Jesse Greiner,Providence Health Care
Dr. Emilia Liana Falcone, Université de Montréal
Gino De Angelis, CADTH (moderator)
Видео COVID-19 Webinar: The Implications of Long COVID канала Canada’s Drug Agency
Dr. Angela Cheung, University of Toronto and Co-lead of CANCOV (Canadian COVID-19 Prospective Cohort Study)
Dr. Jesse Greiner,Providence Health Care
Dr. Emilia Liana Falcone, Université de Montréal
Gino De Angelis, CADTH (moderator)
Видео COVID-19 Webinar: The Implications of Long COVID канала Canada’s Drug Agency
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
There's Always Evidence (Part 2) - Beyond RCTs: The Many Benefits of Observational StudiesCADTH in Conversation with…. Professor Gillian Leng CBE, Chief Executive of NICEINFORMATION SESSION — Introducing CADTH’s New Post-Market Drug Evaluation Program2017 CADTH Symposium: Janet Knox2017 CADTH Symposium: Robyn LimCADTH Drug Reimbursement ReviewsHow CADTH Expert Committees Deliberate2017 CADTH Symposium: Ken MilneRelease of the CADTH Health Economic GuidelinesRecommendation Mapping: A New Approach to Digitizing and Presenting Living GuidelinesThere's Always Evidence Part 3 - Observational Studies: A Deeper DiveDr. Wendy Ungar, Recipient of the 2020 Dr. Jill M. Sanders Award of Excellence in HTAImpact of Zika Virus-Associated Neurological Disorders on Health-Related Quality of Life2018 CADTH Symposium — Oral Presentations: Opioids2018 CADTH Symposium: Dr. Tony Fields, the 2018 Dr. Jill M. Sanders Award RecipientImplementing Health Technology–Related DecisionsToward Standardized Structured Reporting for the Management of Multiple Myeloma in AlbertaThere’s Always Evidence: Part 1COVID-19 and the Surge in Virtual Care: Lessons Learned and Challenges to ComeLaunch of Obstructive Sleep Apnea Recommendations2023 CADTH Symposium — Official Opening